Fmr LLC Arcellx, Inc. Transaction History

Fmr LLC

$1.52 Trillion
Q2 2024

A detailed history of Fmr LLC transactions in Arcellx, Inc. stock. As of the latest transaction made, Fmr LLC holds 6,487,334 shares of ACLX stock, worth $503 Million. This represents 0.02% of its overall portfolio holdings.

Number of Shares

6,487,334

Previous 5,394,495 20.26%

Holding current value

$503 Million

Previous $375 Million 4.57%

% of portfolio

0.02%

Previous 0.03%

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	BUY	$49.74 - $66.98 $54.4 Million - $73.2 Million	1,092,839 Added 20.26%	6,487,334 $358 Million
Q1 2024 May 13, 2024	BUY	$51.85 - $73.49 $52.6 Million - $74.6 Million	1,015,326 Added 23.19%	5,394,495 $375 Million
Q4 2023 Feb 13, 2024	SELL	$31.75 - $57.99 $5.02 Million - $9.17 Million	-158,183 Reduced 3.49%	4,379,169 $243 Million
Q3 2023 Nov 13, 2023	SELL	$31.51 - $37.4 $4.84 Million - $5.75 Million	-153,646 Reduced 3.28%	4,537,352 $163 Million
Q2 2023 Aug 11, 2023	BUY	$27.49 - $46.9 $55.2 Million - $94.2 Million	2,007,908 Added 74.84%	4,690,998 $148 Million
Q1 2023 May 11, 2023	BUY	$26.92 - $33.94 $37.4 Million - $47.2 Million	1,389,490 Added 107.41%	2,683,090 $82.7 Million
Q4 2022 Feb 13, 2023	BUY	$17.18 - $33.0 $8.67 Million - $16.7 Million	504,932 Added 64.02%	1,293,600 $40.1 Million
Q3 2022 Nov 10, 2022	BUY	$16.67 - $22.04 $2.75 Million - $3.64 Million	164,950 Added 26.45%	788,668 $14.8 Million
Q2 2022 Aug 12, 2022	BUY	$7.21 - $24.43 $4.5 Million - $15.2 Million	623,705 Added 4797731.0%	623,718 $11.3 Million
Q1 2022 May 13, 2022	BUY	$12.97 - $19.14 $168 - $248	13 New	13 $0

Others Institutions Holding ACLX

# of Institutions

173

Shares Held

45.6M

Call Options Held

53.6K

Put Options Held

53.7K

View Full List

About Arcellx, Inc.

Ticker ACLX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,819,200
Market Cap $3.4B
Description
Arcellx, Inc., a clinical-stage biotechnology company, engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company's lead ddCAR product candidate is CART-ddBCMA, which is in phase 1 clinical trial for the treatment of patients with relapsed or refractory (r/r) multiple myeloma (MM). It...

More about ACLX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Fmr LLC, based on Form 13F filings with the SEC.

News

Stay updated on Fmr LLC with notifications on news.

Account